Cargando…

Corrigendum to “Presymptomatic Treatment with Acetylcholinesterase Antisense Oligonucleotides Prolongs Survival in ALS (G93A-SOD1) Mice”

Detalles Bibliográficos
Autores principales:	Gotkine, Marc, Rozenstein, Leah, Einstein, Ofira, Abramsky, Oded, Argov, Zohar, Rosenmann, Hanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2015
Materias:	Corrigendum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4352465/ https://www.ncbi.nlm.nih.gov/pubmed/25793201 http://dx.doi.org/10.1155/2015/651934

Ejemplares similares

Presymptomatic Treatment with Acetylcholinesterase Antisense Oligonucleotides Prolongs Survival in ALS (G93A-SOD1) Mice
por: Marc, Gotkine, et al.
Publicado: (2013)

Actions of the antihistaminergic clemastine on presymptomatic SOD1-G93A mice ameliorate ALS disease progression
por: Apolloni, Savina, et al.
Publicado: (2016)

The effect of presymptomatic hypertension in posterior reversible encephalopathy syndrome
por: Lee, Moon Kyu, et al.
Publicado: (2018)

Corrigendum to “From Cryptic Toward Canonical Pre-mRNA Splicing in Pompe Disease: a Pipeline for the Development of Antisense Oligonucleotides”
Publicado: (2016)

Early presymptomatic cholinergic dysfunction in a murine model of amyotrophic lateral sclerosis
por: Casas, Caty, et al.
Publicado: (2013)

Erratum: Huh et al., “Time Course of Alterations in Adult Spinal Motoneuron Properties in the SOD1(G93A) Mouse Model of ALS”
Publicado: (2023)

Improving the Delivery of SOD1 Antisense Oligonucleotides to Motor Neurons Using Calcium Phosphate-Lipid Nanoparticles
por: Chen, Liyu, et al.
Publicado: (2017)

Deregulated expression of cytoskeleton related genes in the spinal cord and sciatic nerve of presymptomatic SOD1(G93A) Amyotrophic Lateral Sclerosis mouse model
por: Maximino, Jessica R., et al.
Publicado: (2014)

Dysregulated expression of death, stress and mitochondrion related genes in the sciatic nerve of presymptomatic SOD1(G93A) mouse model of Amyotrophic Lateral Sclerosis
por: Alves, Chrystian J., et al.
Publicado: (2015)

Corrigendum to “Self-isolation” [J. Math. Econom. 93 (2021) 102483]
por: Baril-Tremblay, Dominique, et al.
Publicado: (2022)

Repeated administration of an acetylcholinesterase inhibitor attenuates nicotine taking in rats and smoking behavior in human smokers
por: Ashare, R L, et al.
Publicado: (2017)

Antisense oligonucleotides in neurological disorders
por: Wurster, Claudia D., et al.
Publicado: (2018)

Molecular Mechanisms of Antisense Oligonucleotides
por: Crooke, Stanley T.
Publicado: (2017)

Antisense oligonucleotides: A primer
por: Scoles, Daniel R., et al.
Publicado: (2019)

Antisense Oligonucleotides and RNA Interference
por: Kher, Gitanjali, et al.
Publicado: (2011)

Corrigendum to “Presymptomatic viral shedding and infective ability of SARS-CoV-2; a case report” [Heliyon 7, (2), (February 2021), Article e06328]
por: Nissen, Karolina, et al.
Publicado: (2022)

Correction to ‘Optimized design of antisense oligomers for targeted rRNA depletion’
por: Phelps, Wesley A, et al.
Publicado: (2021)

T(2)-weighted MRI detects presymptomatic pathology in the SOD1 mouse model of ALS
por: Evans, Matthew C, et al.
Publicado: (2014)

Diels-Alder cycloadditions in water for the straightforward preparation of peptide–oligonucleotide conjugates
por: Marcha´n, Vicente, et al.
Publicado: (2006)

Opportunities and challenges for antisense oligonucleotide therapies
por: Kuijper, Elsa C., et al.
Publicado: (2020)

Silencing Antibiotic Resistance with Antisense Oligonucleotides
por: Jani, Saumya, et al.
Publicado: (2021)

Drug Discovery Perspectives of Antisense Oligonucleotides
por: Kim, Yeonjoon
Publicado: (2023)

In-silico study of antisense oligonucleotide antibiotics
por: Chen, Erica S., et al.
Publicado: (2023)

Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy for Tauopathies
Publicado: (2014)

Reduction of Off-Target Effects of Gapmer Antisense Oligonucleotides by Oligonucleotide Extension
por: Yasuhara, Hidenori, et al.
Publicado: (2022)

Towards next generation antisense oligonucleotides: mesylphosphoramidate modification improves therapeutic index and duration of effect of gapmer antisense oligonucleotides
por: Anderson, Brooke A, et al.
Publicado: (2021)

Description of 3 patients with myasthenia gravis and COVID-19
por: Rein, Netaniel, et al.
Publicado: (2020)

Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically
por: Paizs, Melinda, et al.
Publicado: (2011)

Improved targeting of miRNA with antisense oligonucleotides
por: Davis, Scott, et al.
Publicado: (2006)

Chimeric Antisense Oligonucleotide Conjugated to α-Tocopherol
por: Nishina, Tomoko, et al.
Publicado: (2015)

Antisense Oligonucleotide-Mediated Transcript Knockdown in Zebrafish
por: Pauli, Andrea, et al.
Publicado: (2015)

Therapeutic Potential of Tricyclo-DNA antisense oligonucleotides
por: Goyenvalle, Aurelie, et al.
Publicado: (2016)

Splice-switching antisense oligonucleotides as therapeutic drugs
por: Havens, Mallory A., et al.
Publicado: (2016)

Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease
por: Sardone, Valentina, et al.
Publicado: (2017)

The Future of Antisense Oligonucleotides in the Treatment of Respiratory Diseases
por: Ulanova, Marina, et al.
Publicado: (2012)

Progress in the Use of Antisense Oligonucleotides for Vaccine Improvement
por: Batista-Duharte, Alexander, et al.
Publicado: (2020)

The Challenges and Strategies of Antisense Oligonucleotide Drug Delivery
por: Gagliardi, Maria, et al.
Publicado: (2021)

Inactivating Gene Expression with Antisense Modified Oligonucleotides
por: Altman, Sidney, et al.
Publicado: (2021)

Antisense Oligonucleotide-Based Therapy of Viral Infections
por: Tarn, Woan-Yuh, et al.
Publicado: (2021)

Nonviral delivery systems for antisense oligonucleotide therapeutics
por: Huang, Si, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_01323hfqpls5qvmttc0krneep5